Introduction {#Sec1}
============

Vitamin D is a fat soluble steroid compound performing a variety of functions in the human body. The active form of vitamin D, produced in the kidneys, has a systemic effect. The vitamin produced by other cells performs within the cells or locally. Such effects are the so-called nonclassic functions of vitamin D, such as effect upon proliferation, differentiation, or apoptosis \[[@CR1], [@CR2]\]. Both, the classical functions, i.e., effect upon calcium-phosphate management and the nonclassical ones are imposed by the nuclear receptor (VDR), regulating directly the gene expression \[[@CR3]\].

Vitamin D receptor (VDR) belongs to the nuclear receptors, activated by a ligand and performing as transcription factors \[[@CR4], [@CR5]\].

Reports of the recent years pointed to the occurrence of vitamin D receptor polymorphism \[[@CR6]\]. Initially, *VDR* polymorphism was analysed in disease associated with bone metabolism, yet the studies were gradually extended to comprise the role of vitamin D~3~ receptor in the pathogenesis of other disorders, including the neoplastic diseases \[[@CR6], [@CR7]\].

The *VDR* gene is localized in chromosome 12q12-14. It contains polymorphisms with a functional role. Mutations of the *VDR* gene may be important for the effect of vitamin D upon the cells. The available literature on the effect of concentration and taking vitamin D upon activity, progression, and prognosis in some diseases is scarce, comprises few variables, and often brings contradictory data. The existence of several polymorphisms in the VDR gene has been described using different restriction enzymes. Examples of these include the *Tru*9I, *Taq*I, *Bsm*I, *Eco*RV, and *Apa*I. All these polymorphisms are located between the exons 8 and 9. A different case of RFLP is the so-called FokI. This polymorphism was described in the exon 2.

Polymorphisms of four loci within the *VDR* gene are associated with biological changes in bone mass and density. Those are polymorphisms *Bsm*I, *Taq*I, *Apa*I, and *Fok*I.

A dependency was proved to exist between the mineral density of bones and the variants of the *VDR* gene, coding the receptor protein for vitamin D. The physiological mechanism of the effect of vitamin D receptor genotype polymorphism upon the mineral density of bones has not been fully recognized yet.

Very early effect of vitamin D upon osteogenesis was proved upon discovery of a receptor of this vitamin on the mesenchymal cell. They had been revealed before differentiation to the osseous tissue was started. 1,25-dihydroxycholecalciferol stimulates differentiation of osteoblasts, enhances expression of *VDR* receptors on a growing bone, and stimulates synthesis of type I collagen. It has also been proved that renal metabolite has an intermediate role in stimulation of osteolysis through processes associated with the RANKL pathway and their effect upon both osteoclastogenesis and bone resorption \[[@CR8], [@CR9]\]. It is known that the effect of polymorphism on bone mineral density is not explicit and may interfere with other factors of both genetic and environmental nature. This turned the scientists' efforts towards effects brought by polymorphisms within the *VDR* gene, commencing a new era in studies aimed at identification of genes involved in pathogenesis of osteoporosis.

Therefore, the objective of this study was to define the role of relations of the evaluated gene with the process of postmenopausal osteoporosis, bone density as well as other individual and clinical parameters. The aim was to evaluate frequency of gene *VDR* polymorphism, coding vitamin D~3~ receptor in the female postmenopausal group. The analysis comprised relation of the evaluated genetic variant to the degree of the osseous changes and the osseous turnover, as well as assessment of the role of the evaluated genetic polymorphisms in the etiopathogenesis of osteoporosis. We hypothesized that the polymorphism 283G/A of the gene receptor of vitamin D~3~ is closely related to changes in bone density.

Materials and methods {#Sec2}
=====================

Test group {#Sec3}
----------

The study comprised a group of unrelated Caucasian women inhabiting the region of Wielkopolska. Investigations included 800 women at the postmenopausal age (505) and the reproductive one (295). The postmenopausal group included 314 women with osteoporosis, 110 with osteopenia, and 81 healthy individuals. Densometric measurements were performed to define the bone mineral density (BMD) as well as T-score, Z-score, mean bone mineral density index as compared to the mean value for young adult women (YA-*young adults*) and mean bone mineral density as compared to the mean value for a given age (AM-*age matched*). Additionally, body weight and height were measured to calculate the body mass index.

Detailed history of each patient was taken to gain information on the diseases developed, medication prescribed, age of first and last menstruation, number of deliveries, birth weight as well as smoking habits.

Qualified for genetic tests were those women in whom menopause occurred at least a year ago, who did not receive therapies possibly influencing the bone mass, including selective estrogen receptor modulators---SERM, calcitonin, biposphonates, heparin, steroids, thyroid hormones, antiepileptic drugs, GnRH analogs, tibolon, and underwent no hormonal replacement therapy (HRT). Excluded from the study were patients following bilateral ovariectomy as well as those suffering from endocrine and metabolic disorders, hematological disease, neoplastic conditions, renal disorders, autoimmunologic diseases, or connective tissue diseases, as the above could possibly influence the bony mass. Additionally, a group of Caucasian women at the reproductive age was examined (mean age 27.5 ± 4.7). Consent to perform the study was obtained from the Bioethical Committee.

Bone mineral density (BMD) was measured at the lumbar vertebrae, from vertebra L2 through L4, employing dual energy X-ray absorptiometry (DXA). Densometric tests were performed with the use of LUNAR DPX 100 unit (by Lunar Corporation, Madison, USA). BMD scores were expressed as grams per square centimeter and presented as T-score and Z-score indices, referring to mean BMD values for a given age group. BMD scoring between one standard deviation from the mean age referring to the peak bone mass, measured by the DEXA method, was considered normal (T-score from +1 to −1).

Tests comprised the influence of the evaluated polymorphism upon T-score, Z-score, L2--L4 AM, L2--L4 YA, L2--L4 BMD, BMI as well as other clinical parameters. Results were presented as arithmetic mean with standard deviation. For this purpose, ANOVA analysis of variance was employed. Values adopted as statistically significant were those higher than *p* \< 0.05.

Analysis of gene *VDR* polymorphism by real-time PCR {#Sec4}
----------------------------------------------------

Analysis of polymorphism of 283G/A of gene *VDR* was performed by real-time PCR with the use of LightCycler® 480 designed to ensure quick and accurate polymerase chain reaction. For such procedures, HybProbe hybridization probes were used along with LightCycler® 480 Basic to evaluate the results. Genotyping, i.e., detection of single nucleotide polymorphism of the evaluated genes employed fluorescence measurements taken upon analysis of the melting curve following PCR. LightSNiP set with phials containing proper concentration of starters and probes specific for the amplified fragment was used to test polymorphism of gene *VDR*. Preparation of LightSNiP used for real-time PCR followed the manufacturers' instructions.

The reactions were performed, respectively, throughout 45 cycles for the gene evaluated, covering particular stages of amplification, which was followed by melting of the reaction's products once the temperature reached 95 °C. The genotype was analysed on the basis of the melting curve. The genotype frequency observed upon the recent study was compared to the values expected for genotype distribution at Hardy-Weinberg's equilibrium, using chi-square---*χ*^2^ test. The formula applied was p^2^ + 2pq + q^2^ = 1. Results were presented with 95 % confidence interval (95 % CI).

Statistical analysis of the results employed the software SPSS 17.0 PL for Windows. The database was supplied with clinical parameters of the patients, the genotype frequency, and the evaluated polymorphism allele. The study was planned according to statement of Human and Animal Rights. It has been approved by the local Bioethical Committee in Poznan (no. 1415/03 (158/06)).

Results {#Sec5}
=======

Polymorphism *VDR* 283G/A {#Sec6}
-------------------------

Analysis of frequency of homozygous AA and GG genotypes and the heterozygous AG in polymorphism of 283G/A (G283A) of gene *VDR* showed comparable results in the group with osteoporosis and in healthy postmenopausal females. No statistically significant differences were noted between the groups. More frequent in women with osteoporosis was the heterozygous AG genotype while in healthy women dominating was genotype AA (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1The frequency of occurrence of polymorphism of the *VDR 283G/A* genotypes in women with osteoporosis and without osteoporosis (with osteopenia and healthy ones)Genotype\
VDRWomen with osteoporosisWomen without osteoporosisObserved value\
*n* (%)Expected value\
(%)95 % CIObserved value\
*n* (%)Expected value\
(%)95 % CIGG56 (20.1)12.215.5--23.423 (14.2)12.711.0--16.5AG121 (43.5)45.437.2--52.070 (42.9)45.832.9--45.3AA101 (36.3)42.429.3--44.770 (42.9)41.536.6--48.7Total278 (100)100163 (100)100Table 2The frequency of occurrence of polymorphism of the *VDR 283G/A* genotypes in women with osteopenia and healthy in postmenopausal ageGenotype\
VDRWomen with osteopeniaHealthy womenObserved value\
*n* (%)Expected value\
(%)95 % CIObserved value\
*n* (%)Expected value\
(%)95 % CIGG12 (11.4)11.88.8--16.211 (19.0)12.715.2--24.9AG48 (45.7)45.035.6--55.822 (37.9)45.831.3--41.6AA45 (42.9)43.234.8--51.325 (43.1)41.533.3--50.2Total105 (100)10058 (100)100

Frequency of AA and GG genotypes and the heterozygous AG genotype in polymorphism 283G/A (G283A) of gene *VDR* was comparable in the reproductive age group of women with osteoporosis and in the healthy group. No statistically significant differences were noted between the groups. More frequent in women with osteoporosis was the heterozygous AG genotype, while in young, healthy women higher frequency was shown for the AA genotype (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 3The frequency of occurrence of polymorphism of the *VDR 283G/A* genotypes in women with osteoporosis and osteopenia and healthy in reproductive ageGenotype\
VDRWomen with osteoporosis and osteopeniaHealthy womenObserved value\
*n* (%)Expected value\
(%)95 % CIObserved value\
*n* (%)Expected value\
(%)95 % CIGG68 (17.8)15.916.0--21.951 (17.4)13.613.2--22.2AG169 (44.1)47.937.3--55.3113 (38.9)46.532.7--41.6AA146 (38.1)36.231.4--47.8128 (43.7)39.935.9--50.2Total383 (100)100292 (100)100

Frequency of the homozygous GG genotype in polymorphism 283G/A (G283A) of gene *VDR* differed significantly in women with osteopenia and in the healthy female in postmenopausal age. Higher values were observed in the healthy, postmenopausal group (Table [2](#Tab2){ref-type="table"}). Frequency of AG genotype was slightly higher in osteopenic women. Frequency of AA genotype was comparable in both evaluated groups.

Analysis of frequency of homozygous AA and GG genotypes and the heterozygous AG in polymorphism of 283G/A (G283A) of gene *VDR* showed the results for genotype AA and AG comparable in women with osteoporosis and in the osteopenic group (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Genotype GG was more frequent in women with osteoporosis. Most frequent in both female groups was genotype AG.

Analysis of frequency of homozygous AA and GG genotypes and the heterozygous AG in polymorphism of 283G/A (G283A) of gene *VDR* showed the frequency of GG genotype comparable in women with osteopenia and osteoporosis and in the healthy, postmenopausal group (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). The homozygous AA genotype was more frequent in healthy women while AG genotype prevailed in ill females. Most frequent in both female groups was the heterozygous AG genotype in ill females and AA in healthy women.

Analysis of frequency of homozygous AA and GG genotypes and the heterozygous AG in polymorphism of 283G/A (G283A) of gene *VDR* showed comparable results in women with osteopenia and concurrent osteoporosis and in the healthy females at reproductive age (Table [3](#Tab3){ref-type="table"}). No statistically significant differences were noted.

Frequency of homozygous AA and GG genotypes and the heterozygous AG in polymorphism of 283G/A (G283A) of gene *VDR* was comparable in healthy, postmenopausal women, and in the reproductive age group (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). In both female groups, genotype AA was more frequent.

Influence of *VDR* 283G/A polymorphism on parameters of the evaluated women {#Sec7}
---------------------------------------------------------------------------

Results presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show the value of BMD L2--L4 YA (%) in the evaluated female osteopenic group was significantly higher in women with genotype AA of polymorphism G283A of gene *VDR*, as compared to the same parameter in females with genotype AG and GG. The same table shows that the value of BMD L2--L4 AM (%) in patients with genotype AA of the evaluated gene is lower than with genotype GG, i.e., reversely to BMD L2--L4 YA (%).Table 4Characteristic of the population of healthy women in postmenopausal age taking part in the study of the *VDR* 283G/A polymorphismGenotypeGGAGAAT-score−0.09 ± 0.600.06 ± 0.680.18 ± 0.59Z-score0.65 ± 0.900.70 ± 0.530.60 ± 0.77Body mass (kg)66.93 ± 8.5470.28 ± 8.3768.08 ± 10.33Height (cm)163.73 ± 4.58164.04 ± 5.02162.42 ± 4.16BMI (kg/m^2^)25.01 ± 4.5025.70 ± 3.9825.06 ± 4.13Age55.70 ± 9.0255.60 ± 8.8752.17 ± 8.00Birth weight3508.71 ± 492.323408.66 ± 500.323819.79 ± 473.15Reproductive years37.01 ± 5.0137.56 ± 4.6539.06 ± 5.06Age of menarche13.13 ± 1.5513.02 ± 1.7214.08 ± 1.37Last menstrual period age50.18 ± 4.7350.07 ± 5.0651.37 ± 4.40Number of pregnancies1.91 ± 1.291.97 ± 1.071.99 ± 1.33Years after menopause7.01 ± 4.827.03 ± 5.208.03 ± 4.92BMD L2--L4 (g/cm^2^)1.19 ± 0.071.29 ± 0.081.10 ± 0.19BMD L2--L4 YA (%)101.02 ± 7.7196.02 ± 6.84106.51 ± 7.34BMD L2--L4 AM (%)100.96 ± 8.73104.63 ± 10.71113.54 ± 9.57Table 5Characteristic of the women population with osteopenia taking part in the study of the *VDR* 283G/A polymorphismGenotypeGGAGAAT-score−1.78 ± 0.53−1.94 ± 0.32−1.60 ± 0.47Z-score−0.90 ± 0.52−0.80 ± 0.39−0.75 ± 0.46Body mass (kg)64.39 ± 9.5167.01 ± 8.5265.58 ± 9.84Height (cm)161.02 ± 4.76164.13 ± 4.72163.38 ± 4.87BMI (kg/m^2^)23.02 ± 3.7325.62 ± 4.0324.82 ± 3.92Age53.01 ± 8.1556.13 ± 4.7854.82 ± 3.92Birth weight3298.12 ± 523.483225.81 ± 491.733280.15 ± 527.75Reproductive years39.26 ± 4.8237.82 ± 5.1237.11 ± 4.72Age of menarche13.86 ± 1.0212.47 ± 1.7813.01 ± 1.60Last menstrual period age47.77 ± 4.7850.36 ± 5.0152.82 ± 4.49Number of pregnancies1.90 ± 1.411.95 ± 1.151.91 ± 1.38Years after menopause7.71 ± 4.927.20 ± 5.197.03 ± 4.77BMD L2--L4 (g/cm^2^)0.99 ± 0.050.97 ± 0.060.92 ± 0.04BMD L2--L4 YA (%)\***76.01** ± 4.05**77.28** ± 4.80**90.21** ± 4.35BMD L2--L4 AM (%)\***95.62** ± 8.6788.35 ± 8.44**82.66** ± 7.45Significance of bold entries was observed by *post hoc*analysis\**p*\<0.05

Results presented in Table [6](#Tab6){ref-type="table"} point to the values of BMD L2--L4 AM (%) in the evaluated female population with osteoporosis, significantly lower in women with genotype AA of polymorphism G283A of gene *VDR*, as compared to the same parameter in women with genotype GG.Table 6Characteristic of the women population with osteoporosis taking part in the study of the *VDR* 283G/A polymorphismGenotypeGGAGAAT-score−3.02 ± 0.44−3.32 ± 0.92−3.10 ± 0.26Z-score−1.60 ± 0.60−1.65 ± 0.52−1.58 ± 0.40Body mass (kg)60.01 ± 5.4762.02 ± 7.5864.14 ± 6.82Height (cm)160.96 ± 4.73162.29 ± 4.19160.30 ± 5.00BMI (kg/m^2^)24.04 ± 4.1524.47 ± 3.7023.80 ± 4.01Age56.11 ± 7.5256.03 ± 8.3858.23 ± 7.23Birth weight2930.01 ± 528.733072.82 ± 466.023306.28 ± 506.28Reproductive years36.03 ± 4.6236.92 ± 5.1336.00 ± 4.15Age of menarche13.59 ± 1.8713.06 ± 1.2912.52 ± 1.06Last menstrual period age48.98 ± 4.6548.62 ± 4.7351.06 ± 5.03Number of pregnancies2.62 ± 1.291.89 ± 1.001.96 ± 1.14Years after menopause10.02 ± 5.1411.36 ± 6.0313.27 ± 5.87BMD L2--L4 (g/cm^2^)0.83 ± 0.060.83 ± 0.040.80 ± 0.02BMD L2--L4 YA (%)68.23 ± 5.0172.53 ± 5.3170.81 ± 4.88BMD L2--L4 AM (%)\***81.15** ± 8.3376.28 ± 7.63**66.61** ± 6.73Significance of bold entries was observed by *post hoc*analysis\**p*\<0.05

Discussion {#Sec8}
==========

It is estimated that one billion people worldwide, in particular the elderly inhabitants of US and European cities, shows vitamin D deficiency \[[@CR10]--[@CR12]\]. The level of calcidiol is too low even in 30--50 % of inhabitants of such highly sun-exposed regions like the United Arab Emirates, Turkey, or India \[[@CR13]\]. People of those regions are used to covering their bodies, restricting therefore synthesis of vitamin D. Biologically active, double hydroxylated form of vitamin D---calcitriol---as well as its analogs effect the target cells through VDR.

Lack of direct association between low serum concentration of vitamin D and aggravation of osteopenia and osteoporosis led to the research into other factors which could account for the mechanism of development of hepatic osteodystrophy. Recently, attention has been paid to polymorphism of the receptor gene of vitamin D as a dependency has been shown between bone mineral density and the *VDR* gene variant coding the receptor protein for vitamin D. So far, the physiological mechanism of the effect of polymorphism of receptor genotype for vitamin D upon bone mineral density has not been recognized. It is likely to be associated with disorders of intestinal calcium absorption \[[@CR14]\]. It is claimed that in some diseases, a large group of patients shows excessive or lower presence of particular variants of the *VDR* gene. This was proved by Springer et al. \[[@CR15]\], who observed relations between vitamin D receptor genotype and development of hepatic dystrophy. In patients with allele T of the *VDR* gene, 2--3-fold higher risk of spinal fracture was noted.

Recently, some more reports have confirmed the genetic background of bone mineral density. Even if information on the effect of a given gene or genes are contradictory \[[@CR16]\], the scientists do agree that bone mineral density depends in 75--80 % on the genetic factors \[[@CR16], [@CR17]\]. So far, no single gene was found to prevail over others in the determination of bone mineral density. It is most probably a multi-gene relation \[[@CR16]--[@CR18]\]. Among the number of genes, tested most frequently was the vitamin D receptor gene \[[@CR19], [@CR20]\] or genes coding collagen \[[@CR21]\]. For such reasons, this study chose the gene coding the receptor for active vitamin D metabolites recognized as one with polymorphism likely to affect the osseous tissue density in the patients.

Our studies have shown that females with osteoporosis and osteopenia, with genotype AA, manifest lower values of BMD L2--L4AM, as compared to other genotypes. This proves the relation of vitamin D receptor polymorphism to lower bone density.

Results of the recent study are comparable to those described in literature. Most of the contributions showed no influence of the *VDR* genotype upon the mineral density of the lumbar vertebrae \[[@CR22], [@CR23]\]. Only Sainz et al. \[[@CR24]\], who studied premature Mexican girls, pointed to the effect of the *VDR* gene on BMD throughout the L2--L4 section.

Frequency of *Bsm*I polymorphism of the *VDR* gene in groups evaluated during this study was consistent with Hardy-Weinberg equilibrium. It was observed that distribution of frequency of particular *Bsm*I polymorphism genotype was the same as one observed many years ago by Hustmyer et al. \[[@CR25]\] who evaluated the Caucasian population. Frequency of heterozygotes observed in the recent study was also close to values obtained in the quoted research. The same team observed that the black and yellow race populations showed significant differences in frequency of both alleles (21 and 6 %, respectively for allele B).

In the present study, the presence of GG genotype of the *VDR* gene was statistically lower as compared to other genotypes. It is possible that the result is due to elevated supply of vitamin D~3~, as suggested by Japanese scientists, who noted some relation between vitamin and calcium consumption and the phenotype \[[@CR26]\].

Similar results were obtained following evaluation of the female population in the USA, which showed relations between the *VDR* genotype and the risk of osteoporous bone fractures \[[@CR27]--[@CR29]\]. On the other hand, no relation between bone fractures and the *VDR* gene polymorphism was found in European populations \[[@CR30]\]. Evaluation of Dutch population showed that allele B of *Bsm*I polymorphism of the *VDR* gene is associated with predispositions to bone fractures \[[@CR29]\]. Results confirming correlation of the evaluated alleles with BMD and higher risk of bone fractures were delivered by another Dutch research center \[[@CR27]\].

For a long time now, the *VDR* gene has been accepted as one of the major 'candidate genes' involved in development of osteoporosis. Evidence of genetic susceptibility to osteoporosis could appear as one of the methods used to identify individual predispositions to this disease and as an early prophylactic measure. It should be remembered, however, that in many cases it is the environmental factor that determines development of such disorders. Environmental factors may affect the osseous mass in a variety of ways. Therefore, the evaluated populations should be tested to find any links between the genotype and the phenotype. Some contributions discussing such correlations have already been published \[[@CR31], [@CR32]\].

Evaluation of Polish population showed prevailing allele T of *Taq*I polymorphism of the *VDR* gene in patients with osteoporosis \[[@CR33]\]. As claimed by the authors, this suggests relation between *VDR* polymorphism and the risk of osteoporosis. Data regarding the European and Mexican population bring similar results to confirm such relation \[[@CR34]\]. Some reports point, however, to the lack of relation between the *VDR* gene polymorphism and bone density \[[@CR35]\]. Also, evaluation of Chinese population has not proved significant dependencies between the VDR gene and BMD index. Such diversity of results needs to be clarified, including differences between populations or the environmental factors which could alter genetic predispositions, eventually manifested in different phenotypes \[[@CR36], [@CR37]\].

Remarkable discrepancies have been noted upon comparison of results gained by various teams, investigating this polymorphism of vitamin D receptor, with regard to bone conditions. The major reason, however, is the number of patients comprising the studies. Let us emphasize that our tests have included 800 patients, which places the study among a few projects covering such a large population. It should also be pointed that the population evaluated was highly homogenous. Besides, the women included in the test groups have lived in the area comprised by the study, practically from birth.

Gene mutation may result in altered activation of other genes and/or their products having a major role in the same metabolic pathways. Such a nature of effect has been shown in studies where participation of allele B of the *VDR* gene was associated with the increased risk of osteoporosis. Other studies revealed low BMD scores upon subordination to allele B of the *VDR* gene \[[@CR31], [@CR32]\]. Future studies are needed to confirm the validity of these observations.
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